[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200801169B - Stable solid formulation of sertindole - Google Patents

Stable solid formulation of sertindole

Info

Publication number
ZA200801169B
ZA200801169B ZA200801169A ZA200801169A ZA200801169B ZA 200801169 B ZA200801169 B ZA 200801169B ZA 200801169 A ZA200801169 A ZA 200801169A ZA 200801169 A ZA200801169 A ZA 200801169A ZA 200801169 B ZA200801169 B ZA 200801169B
Authority
ZA
South Africa
Prior art keywords
sertindole
solid formulation
stable solid
stable
formulation
Prior art date
Application number
ZA200801169A
Inventor
Flemming Enok Olsen
Anne Ravnholdt Christensen
Ken Liljegren
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA200801169B publication Critical patent/ZA200801169B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200801169A 2005-09-08 2006-09-06 Stable solid formulation of sertindole ZA200801169B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200501255 2005-09-08

Publications (1)

Publication Number Publication Date
ZA200801169B true ZA200801169B (en) 2010-07-28

Family

ID=37697999

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801169A ZA200801169B (en) 2005-09-08 2006-09-06 Stable solid formulation of sertindole

Country Status (17)

Country Link
EP (1) EP1924261A1 (en)
JP (1) JP2009507051A (en)
KR (1) KR20080042102A (en)
CN (1) CN101257906A (en)
AR (1) AR056475A1 (en)
AU (1) AU2006322460A1 (en)
BR (1) BRPI0615630A2 (en)
CA (1) CA2621866A1 (en)
EA (1) EA013167B1 (en)
IL (1) IL189541A0 (en)
MX (1) MX2008002290A (en)
NO (1) NO20081721L (en)
NZ (1) NZ565330A (en)
TW (1) TW200738239A (en)
UA (1) UA97349C2 (en)
WO (1) WO2007065448A1 (en)
ZA (1) ZA200801169B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2010087462A1 (en) * 2009-01-29 2010-08-05 大日本住友製薬株式会社 Orally disintegrating tablet having inner core
FR2943061B1 (en) * 2009-03-13 2011-02-25 Rhodia Operations ORGANOPHOSPHORUS COMPOUNDS, CATALYTIC SYSTEMS COMPRISING THESE COMPOUNDS, AND HYDROCYANATION OR HYDROFORMYLATION PROCESS USING THESE CATALYTIC SYSTEMS
HUE057925T2 (en) 2012-07-16 2022-06-28 Fibrogen Inc Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CA2914049C (en) * 2013-06-06 2021-10-12 Fibrogen, Inc. Pharmaceutical formulations of a hif hydroxylase inhibitor
US10406103B2 (en) 2013-11-19 2019-09-10 Siga Technologies Inc. Rehydration of micronized tecovirmimat monohydrate
JP2018172361A (en) * 2016-10-14 2018-11-08 大原薬品工業株式会社 Solid preparation containing duloxetine, having improved light stability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04346929A (en) * 1991-05-22 1992-12-02 Takada Seiyaku Kk Bromocriptine mesylate preparation having stability to light
JP2000507544A (en) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー How to treat pain
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
CN101257906A (en) 2008-09-03
TW200738239A (en) 2007-10-16
WO2007065448A1 (en) 2007-06-14
CA2621866A1 (en) 2007-06-14
IL189541A0 (en) 2008-08-07
EA013167B1 (en) 2010-02-26
AU2006322460A1 (en) 2007-06-14
EP1924261A1 (en) 2008-05-28
UA97349C2 (en) 2012-02-10
NO20081721L (en) 2008-04-08
KR20080042102A (en) 2008-05-14
JP2009507051A (en) 2009-02-19
BRPI0615630A2 (en) 2016-11-16
MX2008002290A (en) 2008-03-14
NZ565330A (en) 2011-06-30
EA200800774A1 (en) 2008-06-30
AR056475A1 (en) 2007-10-10

Similar Documents

Publication Publication Date Title
GB2424581B (en) Formulations
PL2335782T3 (en) Use of compositions comprising HFCO-1233zd
ZA200808773B (en) Stable emulsion formulations
IL188915A0 (en) Liquid formulations
ZA200801773B (en) New formulation
EP1909584A4 (en) Prenylflavonoid formulations
TWI370115B (en) New formulation
HK1198914A1 (en) Novel dosage formulation
PT1868586E (en) Anti-inflammatory formulation
IL189935A0 (en) Solid formulation of fungicidal mixtures
ZA200707654B (en) Formulations
EP1951693A4 (en) Solid formulations
IL189541A0 (en) Stable solid formulation of sertindole
EP1894565A4 (en) Stabilized milnacipran formulation
GB0526419D0 (en) Formulation
ZA200802953B (en) Solid vaccine formulation
GB0517673D0 (en) Formulation
HK1120414A1 (en) Pharmaceutical formulation of nitrooxyderivatives of nsaids
LT1928232T (en) Solid formulation
EP1951258A4 (en) Liquid formulations
GB0501030D0 (en) Formulation
GB0500807D0 (en) Formulation
GB0507811D0 (en) Formulation
GB0510788D0 (en) Formulation
GB0526322D0 (en) Formulations